Sophie He/LinkedIn
Aug 12, 2026, 06:01
Sophie He: Exploring Manufacturing Scalability and Cell Separation
Sophie He, Vice President Cell Therapy, Head of M&A and Partnering at Bracco shared a post on LinkedIn:
“In my latest interview with Technology Networks, I explored a critical but often overlooked bottleneck: manufacturing scalability and cell separation.
Cell and gene therapies have opened the potential to curing once – incurable conditions like sickle cell disease.
But approval is only half the story – the real question is, how many patients actually get treated?
Thank you to Izzy Hirst and Anna-Marie MacDonald at Technology Networks for the great conversation.
Full interview here.”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments